6 completed, 3 recruiting, 2 terminated. 6 Phase 3, 2 Phase 2, 2 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 6 | Completed 3, Terminated 2, Recruiting 1 |
| Phase 2 | 2 | Completed 1, Recruiting 1 |
| Phase 4 | 2 | Completed 2 |
Follow IgPro20: new trials by email Literature Review of IgPro20 trials Research Report on IgPro20
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies IgPro20 - Secondary Immune Deficiency | Phase 3 | Recruiting | CSL Behring | 63 | 2026-09-15 | 2026-10-14 |
| Study of IgPro20 to Prevent Infection in People With Multiple Myeloma and Hypogammaglobulinemia IgPro20 - Multiple Myeloma, Hypogammaglobulinemia | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 100 | 2025-05-08 | 2026-10-05 |
| Double-blind, Randomized, Placebo-controlled Study Evaluating Efficacy and Safety of IgPro20 in Post-COVID-19 POTS IgPro20, Placebo - Post-COVID Postural Orthostatic Tachycardia Syndrome | Phase 3 | Terminated | CSL Behring | 16 | 2024-08-28 | 2026-04-13 |
| Hizentra® in Inflammatory Neuropathies - pHeNIx Study Hizentra - Chronic Inflammatory Demyelinating Polyneuropathy | Recruiting | CSL Behring | 100 | 2022-06-10 | 2025-01-07 | |
| A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 in Adults With Dermatomyositis (DM) human immunoglobulin G, Placebo - Dermatomyositis | Phase 3 | Terminated | CSL Behring | 134 | 2019-10-21 | 2025-12-09 |
| Safety and Pharmacokinetics of IgPro20 and IgPro10 in Adults With Systemic Sclerosis (SSc) IgPro20, IgPro10 - Diffuse Cutaneous Systemic Sclerosis | Phase 2 | Completed | CSL Behring | 27 | 2019-09-19 | 2024-02-05 |
| Safety and Tolerability of Higher Infusion Parameters of IgPro20 (Hizentra) in Subjects With Primary Immunodeficiency (PID) IgPro20 - Primary Immunodeficiency | Phase 4 | Completed | CSL Behring | 49 | 2017-02-01 | 2020-03-25 |
| Study of Immune Deficiency Patients Treated With Subcutaneous Immunoglobulin (IgPro20, Hizentra®) on Weekly and Biweekly Schedules Subcutaneous Immune Globulin (Human) (Hizentra) - Primary Immune Deficiency, Secondary Immune Deficiency | Phase 4 | Completed | CSL Behring | 26 | 2016-03-15 | 2018-02-26 |
| Extension Study of Maintenance Treatment With Subcutaneous Immunoglobulin (IgPro20) for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) IgPro20 - Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | Phase 3 | Completed | CSL Behring | 82 | 2014-07-30 | 2018-10-02 |
| Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (EU Extension Study) IgPro20 - Primary Immunodeficiency (PID) | Phase 3 | Completed | CSL Behring | 40 | 2008-08-01 | 2014-04-02 |
| Extension Study of Subcutaneous Immunoglobulin Human in Patients With Primary Immunodeficiency (PID) IgPro20 - Primary Immune Deficiency | Phase 3 | Completed | CSL Behring | 21 | 2008-06-01 | 2014-04-02 |
Primary Immunodeficiency Diseases (4) · Agammaglobulinemia (2) · Multiple Myeloma (2) · Polyradiculoneuropathy, Chronic Inflammatory Demyelinating (2) · Burkitt Lymphoma (1) · Common Variable Immunodeficiency (1) · Dermatomyositis (1) · Hematologic Neoplasms (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Scleroderma, Diffuse (1)
CSL Behring (10) · Memorial Sloan Kettering Cancer Center (1)
United States (7) · Canada (5) · France (5) · Germany (5) · Italy (4) · Poland (4) · Spain (4) · United Kingdom (4) · Australia (2) · Belgium (2) · Czechia (2) · Japan (2) · Switzerland (2) · Argentina (1) · Denmark (1)
Elie Haddad, MD (1) · Zainab Shahid, MBBS (1)
PMID 24412910, PMID 33025378, PMID 33409867, PMID 39909490
2018 (2), 2023 (2), 2008 (1), 2015 (1), 2016 (1)